New FDA Initiatives: Project Orbis and Real-Time Oncology Review
Oct30

New FDA Initiatives: Project Orbis and Real-Time Oncology Review

The U.S. Food and Drug Administration (FDA) recently announced two exciting and innovative initiatives from FDA’s Oncology Center of Excellence: Project Orbis and Real-Time Oncology Review (RTOR) Pilot Program. Project Orbis Project Orbis, an initiative of the FDA Oncology Center of Excellence (OCE), will provide a framework for concurrent submission and review of oncology products between international partners. The...

Read More
FDA Renews Licenses for Synchrogenix’s GlobalSubmit eCTD Software
Sep25

FDA Renews Licenses for Synchrogenix’s GlobalSubmit eCTD Software

The US FDA has renewed its legacy licenses for Synchrogenix’s eCTD review and validation software, GlobalSubmit REVIEW and GlobalSubmit VALIDATE for another year.

Read More
Reminder: Establishment Registration Renewals are Due by EOY
Oct02

Reminder: Establishment Registration Renewals are Due by EOY

FDA Establishment Registration renewals for 2019 must be submitted between October 1 and December 31. With certain exemptions, any establishment engaged in the manufacture, repacking, relabeling, or salvaging of a drug product for commercial distribution is required to register with FDA annually. Registration is required within five days of introducing a product into commercial distribution.

Read More
Trial Summary Dataset: An Overview
May01

Trial Summary Dataset: An Overview

The Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM) Trial Summary dataset has become increasingly useful to reviewers.  The Trial Summary (TS) dataset allows the sponsor to submit a high-level overview of the trial in a structured format. Each record in the Trial Summary dataset contains the value of a parameter, a characteristic of the trial. For example, a Trial Summary dataset is used to record basic information about the study such as trial phase, protocol title, and trial objectives. The Trial Summary dataset contains information about the planned and actual trial characteristics.

Read More
EMA Reasons for Rejection of CCI
Mar27

EMA Reasons for Rejection of CCI

New data from European Medicines Agency (EMA) confirms the tough position EMA is taking in regard to commercially confidential information (CCI). According to the European Medicines Agency’s “EMA Update on Clinical Data Publication” published on 29 January, 2018, 76% of CCI instances were rejected in 2017. Interestingly, the EMA has provided further insight on how they are considering CCI by citing five reasons for rejection.

Read More